Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Amyris signs exclusive license agreement with Croda International » 08:01
05/19/23
05/19
08:01
05/19/23
08:01
AMRS

Amyris

/

+

Amyris announced that it…

Amyris announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International for the supply of sustainable squalene. Amyris' squalene is a biofermentation-based adjuvant developed using Amyris' unique Lab-to-Market technology platform. Squalene, used in adjuvants to boost immune responses, is commonly derived from shark liver. Amyris' sugarcane-derived, sustainable squalene is molecularly identical to the traditional shark source, offering a higher purity and a more predictable cost profile compared to sourcing directly from sharks. Under the terms of the agreement, Amyris will manufacture and supply squalene to Croda and Croda will license squalene technology from Amyris to market, distribute, and sell squalene as an excipient, or as an ingredient in formulated products for use in human and veterinary vaccines, drug delivery systems, or nucleic acid delivery systems. Croda will also leverage its experience with good manufacturing practices for the pharmaceutical industry and accelerate commercialization of the final packaged squalene products. In addition to an upfront payment of $4M and a future - performance based - milestone payment of $4M, Amyris will receive a share of profits generated from the sale of squalene excipients and formulated products incorporating Amyris' squalene technology for use in the vaccine field.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

05/18/23 Jefferies
Amyris downgraded to Hold from Buy at Jefferies
05/10/23 TD Cowen
Amyris downgraded to Market Perform at TD Cowen after going concern disclosure
05/10/23 TD Cowen
Amyris downgraded to Market Perform from Outperform at TD Cowen
04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Downgrade
Amyris downgraded to Hold from Buy at Jefferies » 05:03
05/18/23
05/18
05:03
05/18/23
05:03
AMRS

Amyris

/

+

Jefferies analyst…

Jefferies analyst Laurence Alexander downgraded Amyris to Hold from Buy with a price target of 65c, down from $3.10. While new asset monetizations and the Givaudan deal address the company's near-term liquidity crunch, pulling value forward from milestones and royalty agreements also appears likely to come with concessions at the expense of 2024-2028, the analyst tells investors in a research note. In addition, the path for Amyris' ore profitability likely faces additional challenges in the second half of 2023 as the credit cycle leads to a tougher U.S. consumer environment, contends the firm.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

05/10/23 TD Cowen
Amyris downgraded to Market Perform at TD Cowen after going concern disclosure
05/10/23 TD Cowen
Amyris downgraded to Market Perform from Outperform at TD Cowen
04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Downgrade
Amyris downgraded to Market Perform at TD Cowen after going concern disclosure » 07:26
05/10/23
05/10
07:26
05/10/23
07:26
AMRS

Amyris

/

+

As previously reported,…

As previously reported, TD Cowen downgraded Amyris to Market Perform from Outperform with a price target of $1.25, down from $4. Uncertainties on additional cash from divestitures and earnout advancements necessary to self fund has triggered a going concern disclosure, notes the firm, which says the lack of details to solve for the company's cash needs moves the firm to the sidelines.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

05/10/23 TD Cowen
Amyris downgraded to Market Perform from Outperform at TD Cowen
04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Downgrade
Amyris downgraded to Market Perform from Outperform at TD Cowen » 07:00
05/10/23
05/10
07:00
05/10/23
07:00
AMRS

Amyris

/

+

TD Cowen analyst Steven…

TD Cowen analyst Steven Mah downgraded Amyris to Market Perform from Outperform with a price target of $1.25, down from $4.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Earnings
Amyris reaffirms FY23 revenue view up 95%-100% » 16:36
05/09/23
05/09
16:36
05/09/23
16:36
AMRS

Amyris

/

+

The company said,…

The company said, "Our current outlook for the FY23, including revenue guidance provided by the company on March 15, 2023, remains unchanged. In connection with the company's ongoing strategic review, as previously communicated on April 24, 2023, the company is focused on cost efficiency, capital structure, and liquidity required to fund the business. The company updated its going concern disclosure in its quarterly report on Form 10-Q and has signed forbearance agreements with the company's lenders, Foris Ventures, LLC, Perrara Ventures, LLC, and DSM Finance B.V. relating to the maturity of an aggregate $92.5M of debt principal. The lenders have agreed to forbear from exercising any rights and remedies with respect to certain payment defaults until June 23, 2023."

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Earnings
Amyris reports Q1 EPS (53c), consensus (32c) » 16:35
05/09/23
05/09
16:35
05/09/23
16:35
AMRS

Amyris

/

+

Reports Q1 revenue…

Reports Q1 revenue $56.1M, consensus $53.04M. "During Q1, we were very focused on our liquidity and cost control efforts," commented John Melo, President and CEO. "We expanded the Fit-to-Win scope to all aspects of our operations and entered into a strategic review of our cost structure and liquidity plans to continue to support growth across the portfolio and achieve profitability. We have much more to do on our Fit-to-Win agenda. To fully leverage our assets and drive enterprise value, we are focused on efficiency, lowering costs, and simplifying our portfolio."

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Options
Amyris options imply 20.6% move in share price post-earnings » 14:49
05/09/23
05/09
14:49
05/09/23
14:49
AMRS

Amyris

/

+

Pre-earnings options…

Pre-earnings options volume in Amyris is 1.7x normal with calls leading puts 7:5. Implied volatility suggests the market is anticipating a move near 20.6%, or 0c, after results are released. Median move over the past eight quarters is 13.5%.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Options
Unusually active option classes on open May 1st » 09:40
05/01/23
05/01
09:40
05/01/23
09:40
AMRS

Amyris

/

+

, IEI

iShares 3-7 Year Treasury Bond ETF

$117.99 /

+0.53 (+0.45%)

, BROS

Dutch Bros

$31.16 /

+0.27 (+0.87%)

, SOFI

SoFi Technologies

$6.23 /

+ (+0.00%)

, TFC

Truist Financial

$32.57 /

+1.18 (+3.76%)

, NCLH

Norwegian Cruise Line

$13.35 /

+ (+0.00%)

, MGM

MGM Resorts

$44.90 /

-0.01 (-0.02%)

, FCEL

FuelCell

$1.89 /

+ (+0.00%)

, ON

ON Semiconductor

$71.92 /

+ (+0.00%)

, W

Wayfair

$34.82 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Amyris (AMRS), iShares Barclays 3 to 7 Year Treasury Bond Fund (IEI), Dutch Bros (BROS), SoFi Technologies (SOFI), Truist Financial (TFC), Norwegian Cruise Lines (NCLH), MGM Resorts (MGM), FuelCell (FCEL), ON Semiconductor (ON), and Wayfair (W).

ShowHide Related Items >><<
W Wayfair
$34.82 /

+ (+0.00%)

TFC Truist Financial
$32.57 /

+1.18 (+3.76%)

SOFI SoFi Technologies
$6.23 /

+ (+0.00%)

ON ON Semiconductor
$71.92 /

+ (+0.00%)

NCLH Norwegian Cruise Line
$13.35 /

+ (+0.00%)

MGM MGM Resorts
$44.90 /

-0.01 (-0.02%)

FCEL FuelCell
$1.89 /

+ (+0.00%)

BROS Dutch Bros
$31.16 /

+0.27 (+0.87%)

AMRS Amyris
/

+

AMRS Amyris
/

+

04/28/23 Canaccord
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord
04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
IEI iShares 3-7 Year Treasury Bond ETF
$117.99 /

+0.53 (+0.45%)

BROS Dutch Bros
$31.16 /

+0.27 (+0.87%)

04/05/23 Wedbush
Dutch Bros upgraded to Outperform from Neutral at Wedbush
04/04/23 Stifel
Dutch Bros price target lowered to $36 from $37 at Stifel
02/16/23 Guggenheim
Guggenheim starts Dutch Bros at Neutral following 45% year-to-date rally
02/16/23 Guggenheim
Dutch Bros initiated with a Neutral at Guggenheim
SOFI SoFi Technologies
$6.23 /

+ (+0.00%)

04/03/23 MoffettNathanson
MoffettNathanson sees Wyndham deal strengthening SoFi Home Lending franchise
02/15/23 Mizuho
SoFi Technologies price target raised to $9 from $6 at Mizuho
01/31/23 Citi
SoFi shares remain a buy after 'solid beat,' says Citi
01/31/23 Morgan Stanley
SoFi Technologies price target raised to $6 from $5 at Morgan Stanley
TFC Truist Financial
$32.57 /

+1.18 (+3.76%)

04/21/23 RBC Capital
Truist Financial price target lowered to $46 from $54 at RBC Capital
04/21/23 Piper Sandler
Truist Financial price target lowered to $46 from $53 at Piper Sandler
04/21/23 Credit Suisse
Truist Financial price target lowered to $40 from $52 at Credit Suisse
04/12/23 Barclays
Truist Financial price target lowered to $44 from $57 at Barclays
NCLH Norwegian Cruise Line
$13.35 /

+ (+0.00%)

04/28/23 JPMorgan
Norwegian Cruise Line initiated with a Neutral at JPMorgan
03/29/23 Susquehanna
Norwegian Cruise Line price target lowered to $15 from $20 at Susquehanna
03/23/23 Truist
Norwegian Cruise Line price target lowered to $17 from $21 at Truist
03/01/23 Stifel
Norwegian Cruise Line selloff creates buying opportunity, says Stifel
MGM MGM Resorts
$44.90 /

-0.01 (-0.02%)

04/21/23 Barclays
MGM Resorts price target raised to $60 from $59 at Barclays
04/20/23 Stifel
Las Vegas Sands price target raised to $73 from $66 at Stifel
04/18/23 Truist
MGM Resorts price target raised to $57 from $54 at Truist
04/12/23 JPMorgan
MGM Resorts price target raised to $55 from $54 at JPMorgan
FCEL FuelCell
$1.89 /

+ (+0.00%)

12/21/22 B. Riley
FuelCell price target lowered to $4 from $5 at B. Riley
12/14/22 UBS
FuelCell initiated with a Neutral at UBS
12/13/22 UBS
FuelCell initiated with a Neutral at UBS
10/21/22 Canaccord
FuelCell assumed with a Hold at Canaccord
ON ON Semiconductor
$71.92 /

+ (+0.00%)

03/28/23 Wells Fargo
Wells Fargo sees Infineon's increased expectations as positive for NXP, others
03/08/23 BofA
ON Semiconductor price target raised to $100 from $90 at BofA
03/03/23 Citi
Tesla announcement not near-term risk for ON Semiconductor, says Citi
03/02/23 Stifel
Long-term implications of Tesla news remain unclear for ON Semi, says Stifel
W Wayfair
$34.82 /

+ (+0.00%)

04/27/23 Citi
Wayfair demand trends stabilizing, says Citi
04/26/23 Piper Sandler
Wayfair price target lowered to $35 from $42 at Piper Sandler
04/24/23 BofA
Bed Bath bankruptcy could be 'modest tailwind' for Wayfair, Overstock, says BofA
03/07/23 Truist
Wayfair price target lowered to $47 from $50 at Truist
W Wayfair
$34.82 /

+ (+0.00%)

TFC Truist Financial
$32.57 /

+1.18 (+3.76%)

SOFI SoFi Technologies
$6.23 /

+ (+0.00%)

ON ON Semiconductor
$71.92 /

+ (+0.00%)

NCLH Norwegian Cruise Line
$13.35 /

+ (+0.00%)

MGM MGM Resorts
$44.90 /

-0.01 (-0.02%)

FCEL FuelCell
$1.89 /

+ (+0.00%)

BROS Dutch Bros
$31.16 /

+0.27 (+0.87%)

AMRS Amyris
/

+

  • 24
    Aug
  • 16
    Aug
W Wayfair
$34.82 /

+ (+0.00%)

TFC Truist Financial
$32.57 /

+1.18 (+3.76%)

SOFI SoFi Technologies
$6.23 /

+ (+0.00%)

NCLH Norwegian Cruise Line
$13.35 /

+ (+0.00%)

MGM MGM Resorts
$44.90 /

-0.01 (-0.02%)

W Wayfair
$34.82 /

+ (+0.00%)

TFC Truist Financial
$32.57 /

+1.18 (+3.76%)

SOFI SoFi Technologies
$6.23 /

+ (+0.00%)

ON ON Semiconductor
$71.92 /

+ (+0.00%)

NCLH Norwegian Cruise Line
$13.35 /

+ (+0.00%)

MGM MGM Resorts
$44.90 /

-0.01 (-0.02%)

FCEL FuelCell
$1.89 /

+ (+0.00%)

BROS Dutch Bros
$31.16 /

+0.27 (+0.87%)

AMRS Amyris
/

+

W Wayfair
$34.82 /

+ (+0.00%)

TFC Truist Financial
$32.57 /

+1.18 (+3.76%)

SOFI SoFi Technologies
$6.23 /

+ (+0.00%)

ON ON Semiconductor
$71.92 /

+ (+0.00%)

NCLH Norwegian Cruise Line
$13.35 /

+ (+0.00%)

MGM MGM Resorts
$44.90 /

-0.01 (-0.02%)

FCEL FuelCell
$1.89 /

+ (+0.00%)

BROS Dutch Bros
$31.16 /

+0.27 (+0.87%)

AMRS Amyris
/

+

Over a month ago
Initiation
Amyris initiated with Buy into 'biotech beauty boom' at Canaccord » 06:34
04/28/23
04/28
06:34
04/28/23
06:34
AMRS

Amyris

/

+

Canaccord analyst Susan…

Canaccord analyst Susan Anderson initiated coverage of Amyris with a Buy rating and $1.50 price target. Amyris is a consumer biotechnology company that develops and manufactures sustainable ingredients mainly for beauty and food and has also developed consumer brands focused on clean, green, and sustainability, the analyst tells investors in a research note. As consumers continue to gravitate toward clean, green, and sustainable products, a "biotech beauty boom is on the horizon," says the firm. It believes Amyris "can emerge a winner" given its sustainable molecule offering, combined with its clean consumer offering.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

04/28/23 Canaccord
Amyris initiated with a Buy at Canaccord
04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
03/16/23 TD Cowen
Amyris price target lowered to $4 from $6 at TD Cowen
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Initiation
Amyris initiated with a Buy at Canaccord » 05:22
04/28/23
04/28
05:22
04/28/23
05:22
AMRS

Amyris

/

+

Canaccord analyst Susan…

Canaccord analyst Susan Anderson initiated coverage of Amyris with a Buy rating and $1.50 price target.

ShowHide Related Items >><<
AMRS Amyris
/

+

AMRS Amyris
/

+

04/26/23 Piper Sandler
Amyris price target lowered to $1 from $1.50 at Piper Sandler
03/16/23 Piper Sandler
Amyris price target lowered to $1.50 from $2 at Piper Sandler
03/16/23 TD Cowen
Amyris price target lowered to $4 from $6 at TD Cowen
03/16/23 H.C. Wainwright
Amyris price target lowered to $5 from $22 at H.C. Wainwright
AMRS Amyris
/

+

AMRS Amyris
/

+

AMRS Amyris
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.